Ascentage Closes $150 Million C Round to Develop Apoptosis Drugs

Ascentage Pharma of Shanghai closed a $150 million Series C financing to continue developing its portfolio of apoptosis therapies for cancer and other diseases. Ascentage, based on its small-molecule technology that targets protein-protein interactions, has developed seven candidates that are being tested in 16 clinical trials for cancer, hepatitis B and age-related diseases. The trials are being conducted in the US, China and Australia. The company said its latest financing brought total capital raised to around $240 million. More details....

Share this with colleagues:

Original Article: Ascentage Closes $150 Million C Round to Develop Apoptosis Drugs

More From BioPortfolio on "Ascentage Closes $150 Million C Round to Develop Apoptosis Drugs"